First clinical trial to test a new all-oral regimen for extensively drug-resistant TB; Nix-TB is a critical step in the development of a universal treatment for all types of TB.

TUCSON, Ariz., April 29, 2015 — The non-profit Critical Path Institute has been selected to host a new tuberculosis (TB) clinical trial data sharing platform. The initiative will start by creating a common database from three Phase III clinical trials earlier supported by the Special Programme for Research and Training in Tropical Diseases (TDR), the TB Alliance and St. George’s, University of London.

TB Alliance, a not-for-profit product development partnership with the mission of developing better, faster, and affordable drugs for tuberculosis (TB), has received a grant from the Australian Department of Foreign Affairs and Trade (DFAT) to support late-stage clinical trials of new TB treatments. The grant was announced at a World TB Day event in Canberra, Australia as part of a larger investment of support for new tools to tackle diseases that endanger public health in the region.

TB Alliance has announced a new partnership with the U.S. Fund for UNICEF that will dramatically increase the scope and impact of child and maternal health programs around the world to include the diagnosis and treatment of pediatric tuberculosis (TB), a significant cause of child mortality.

STAND trial will take place in approximately 50 study sites in Africa, Asia, Caribbean, Eastern Europe, and Latin America; Results published in The Lancet show PaMZ’s promise to dramatically shorten and simplify therapy for patients with drug-resistant TB; Regimen could improve treatment for those with drug-sensitive TB and those with HIV co-infection.

Phase 3 STAND trial launched to advance PaMZ through final stage of testing.

TBA-354 is the first potential tuberculosis drug to advance to Phase 1 trial in six years.

Results of study testing BPaZ published in American Journal of Respiratory and Critical Care Medicine; Regimen now being tested in Phase 2b clinical trial

This webinar highlights the opportunities, challenges, as well as lessons learned in making child-friendly TB treatments available on a sustainable basis.

NEW YORK, Jan. 13, 2015 /PRNewswire-USNewswire/ -- TB Alliance, an international not-for-profit organization with the mission of developing improved tuberculosis (TB) treatments, announced the appointment of Mario Raviglione, MD, director of the Global TB Programme at the World Health Organization (WHO), and Shalini Sharp, the chief financial officer of Ultragenyx Pharmaceutical Inc., to its Board of Directors.